Are drug labels static or dynamic?

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 302-304

  Seminerio, M J ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYP2C8 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

DRUG INTERACTION; DRUG LABELING; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; ORGANIZATION AND MANAGEMENT; TRENDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZAMIDES; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; DRUG LABELING; HUMANS; PIPERAZINES; PYRIMIDINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883200188     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.109     Document Type: Review

References (10)

1. Peng, B., Lloyd, P. & Schran, H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44, 879-894 (2005).
2. Wieczner, J. Will Novartis decision impact US drug prices MarketWatch. Wall Street Journal (1 April 2013). (1 April 2013
3. Filppula, A.M., Neuvonen, M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug. Metab. Dispos. 41, 50-59 (2012).
4. Filppula, A.M., Tornio, A., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin. Pharmacol. Ther. 94, 383-393 (2013).
5. Gurney, H. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33-40 (2007).
6. Nebot, N., Crettol, S., d'Esposito, F., Tattam, B., Hibbs, D.E. & Murray, M. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br. J. Pharmacol. 161, 1059-1069 (2010).
7. Ratain, M.J. Dear Doctor: We really are not sure what dose of capecitabine you should prescribe for your patient. J. Clin. Oncol. 20, 1434-1435 (2002).
8. Midgley, R. & Kerr, D.J. Capecitabine: have we got the dose right? Nat. Clin. Pract. Oncol. 6, 17-24 (2009).
9. Murray, B., Bates, J. & Buie, L. Impact of a new assay for measuring serum creatine levels on carboplatin dosing. Am. J. Health Syst. Pharm. 69, 1136-1141 (2012).
10. Kang, S.P., & Ratain, M.J. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin. Cancer Res.16, 4446-4451 (2010).